After nine years as the world’s biggest maker of medicines, Pfizer is set to cede its crown next year to a company that a decade ago few would have predicted to be leading the pharma league tables – Sanofi.
PLX-PAD cells from Pluristem Therapeutics, Inc. met all the clinical studies’ protocol endpoints, demonstrating a safe immunologic profile at all dosage levels and found to be potentially effective in treating patients suffering from critical limb ischemia.
Following ImmuPharma’s Investigational New Drug filing with the FDA and the successful completion of a Phase 2b study, the FDA has granted Lupuzor Fast Track designation.
Federal health experts are recommending that use of Merck's blockbuster cholesterol drug Vytorin be expanded to patients with kidney disease, but not those with late-stage disease who are on dialysis.
Procter & Gamble Co. said that it has combined some of its drug units with Jerusalem-based Teva Pharmaceutical Industries Ltd., a move that should help the companies expand in China and other emerging markets.
Drug maker GlaxoSmithKline PLC said that it has agreed in principle with the United States government on a $3 billion settlement of investigations of the company's sales and marketing practices.
To sustain medical innovation, the U.S. Food and Drug Administration must accelerate the adoption of a benefit-risk framework to inform decision-making in the regulatory process.
Regulus Therapeutics Inc. announced that the Australian Patent Office has granted claims in the ‘Sarnow’ patent series for microRNA-122 therapy in the treatment of hepatitis C viral infections.
Researchers have figured out how Helicobacter pylori attacks a cell’s energy infrastructure, sparking a series of events in the cell that ultimately lead it to self-destruct.
AVI BioPharma Inc. announced positive safety results from the first five cohorts of Phase 1 single ascending dose trials of AVI-6002 and AVI-6003.
The Committee for Medicinal Products for Human Use adopted a positive opinion on the Gilead Sciences Inc ‘s marketing authorization application for the once-daily single-tablet regimen, Eviplera.
Genticel has completed the recruitment of patients participating in its Phase 1 clinical trial with a liquid formulation of ProCervix.
Cresset has released its latest version of the bioisostere replacement tool, FieldStere. FieldStere uses Cresset’s field-point technology, together with a database of molecular fragments, to help guide drug discovery projects.
The PiezoXpert from Eppendorf is designed for piezo-assisted microinjection or manipulation techniques. Digital programmable parameter setting allows the user to perforate cell membranes with the utmost accuracy and reproducibility.
Selventa, a personalized healthcare company, has formed a strategic scientific alliance with Linguamatics, a software solutions company that provides knowledge extraction through its I2E natural language processing text mining platform.